Xylazine: Evaluation of antemortem and postmortem specimen storage conditions

Clicks: 14
ID: 329046
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #37 of 61 articles by views in journal of analytical toxicology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Xylazine, a popular compound found independently and in polydrug mixtures throughout the United States, is intended for use in veterinary medicine and not for human consumption. When xylazine is ingested by humans, life-threatening central nervous system depression responses could potentially occur. With its increase in prevalence, several methods of detection were developed within forensic toxicology. Since xylazine is not approved for human clinical use, little is known about its behavior, such as its stability in stored biological matrices. Knowledge of drug stability in biological matrices can provide critical insight on the limitations surrounding specimen storage conditions, which is of great importance in forensic toxicology. This study assessed the stability of xylazine in preserved antemortem and postmortem blood under three storage conditions (23 °C, 2-8 °C, and -20 °C) at two concentrations (3 ng/mL and 160 ng/mL). Once prepared, samples were extracted using a validated protein precipitation procedure and analyzed by liquid chromatography-tandem mass spectrometry. Xylazine was considered stable if the deviation in calculated concentration was within ±20% of the Day 0 concentration. When the results of each individual pool prepared were averaged for reporting, the following results were obtained. When stored at 23 °C in both matrices, xylazine was unstable by Day 7 at 3 ng/mL and unstable by Day 10 at 160 ng/mL. When stored between 2-8 °C in antemortem blood, xylazine was unstable by Day 10 at 3 ng/mL and unstable by Day 24 at 160 ng/mL. When stored between 2-8 °C in postmortem blood, xylazine was unstable by Day 29 at both 3 and 160 ng/mL. When stored at -20 °C in antemortem blood, xylazine was unstable by Day 3 at both 3 ng/mL and 160 ng/mL. When stored at -20 °C in postmortem blood, xylazine was unstable by Day 21 at 3 ng/mL and unstable by Day 10 at 160 ng/mL.
Reference Key
openalex_W7213534156 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Paige Riley‐Carrier, Rebecca Wagner
Journal journal of analytical toxicology
Year 2026
DOI
10.1093/jat/bkag081
URL
https://doi.org/10.1093/jat/bkag081
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.